Long-term safety and efficacy of omeprazole in gastro-oesophageal reflux disease

Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas

Proton pump inhibitors are being increasingly used and for longer periods of time, especially in patients with gastroesophageal reflux disease. Each of these trends has led to numerous studies and reviews of the potential risk-benefit ratio of the long-term use of proton pump inhibitors. Both long-term effects of hypergastrinaemia due to the profound acid suppression caused by proton pump inhibitors as well as the effects of hypo-/achlorhydria per se have been raised and studied. Potential areas of concern that have been raised in the long-term use of proton pump inhibitors, which could alter this risk-benefit ratio include: gastric carcinoid formation; the development of rebound acid hypersecretion when proton pump inhibitor treatment is stopped; the development of tolerance; increased oxyntic gastritis in H. pylori patients and the possibility of increasing the risk of gastric cancer; the possible stimulation of growth of non-gastric tumours due to hypergastrinaemia; and the possible effect of the hypo/achlorhydria on nutrient absorption, particularly iron and vitamin B12. Because few patients with idiopathic gastro-oesophageal reflux disease/peptic ulcer disease have been treated long-term (i.e., >10 years), there is little known to address the above areas of potential concern. Most patients with gastrinomas with Zollinger-Ellison syndrome have life-long hypergastrinaemia, require continuous proton pump inhibitors treatment and a number of studies report results of >5-10 years of tratment and follow-up. Therefore, an analysis of Zollinger-Ellison syndrome patients can provide important insights into some of the safety concerns raised above. In this paper, results from studies of Zollinger-Ellison syndrome patients and other recent studies dealing with the safety concerns above, are briefly reviewed.

Stomach myoelectrical response of patients with gastroesophageal reflux disease receiving omeprazole treatment

BACKGROUND AND AIM

Proton pump inhibitor treatment is effective for gastroesophageal reflux disease (GERD). It is unknown whether these agents effect any change in the stomach myoelectricity of GERD patients. Electrogastrographic (EGG) recording was used to study the probable effect of omeprazole on GERD patients.

METHODS

Nineteen endoscopically confirmed GERD patients and 38 dyspepsia-free controls were invited to receive EGG recording. After daily omeprazole treatment for 4 weeks, the symptomatic response of GERD patients was scaled, healing of erosive esophagitis was endoscopically assessed, and EGG recording was repeated for comparison.

RESULTS

Before treatment, GERD patients and controls displayed similar dominant frequency, whereas the former had higher dominant power compared with controls, either in fasting (29.2 +/- 6.0 dB compared with 25.3 +/- 3.8 dB, P < 0.01) or postprandial (31.9 +/- 5.6 dB compared with 27.7 +/- 3.8 dB, P < 0.001) recording. They also had diminished percentile normal rhythm (2-4 c.p.m.), irrespective of fasting (40.2 +/- 14.5% compared with 65.8% +/- 23.5%, P < 0.001) or postprandial (47.5 +/- 23.3% compared with 77.9 +/- 16.8%, P < 0.001) recording. After omeprazole treatment, healing was achieved in 12 patients (63.2%). Among the abnormal EGG parameters, only the postprandial percentile normal rhythm was restored (47.5 +/- 23.3% compared with 65.2 +/- 20.8%, P < 0.01).

CONCLUSIONS

Gastroesophageal reflux disease patients may have obvious dysrhythmia and higher myoelectrical power. Effective omeprazole treatment only improves the postprandial myoelectrical regularity, whereas abnormal EGG parameters remain impaired.

The clinical importance of proton pump inhibitor pharmacokinetics

Achieving the optimal clinical response for patients with upper gastrointestinal peptic disease is important. This response depends on the pathology treated as well as on the choice of proton pump inhibitor. Here, we identify factors in specific disease therapy and proton pump inhibitor (PPI) pharmacokinetic and pharmacodynamic characteristics that help us achieve this goal. These include differences in PPI bioavailability and acid-suppressive effects. Available data indicate that PPIs appear to have similar potency on a milligram basis, and that omeprazole and lansoprazole are more frequently double dosed than pantoprazole. The lower propensity for double dosing with pantoprazole may also result in lower medication acquisition costs and a reduction in physician visits due to ineffective therapy with the standard dosing of these other agents.

Gastric mucosal morphological consequences of acid suppression: a balanced view

In the chapter, an analysis of the literature on the relationship between Helicobacter pylori, the use of proton pump inhibitors and the development of atrophic gastritis is presented, and the difficulties of classifying gastritis and the new possibilities of quantifying chronic inflammation by morphometric analysis are discussed. The issue surrounding the necessity of eradicating H. pylori in H. pylori-positive patients has still not been solved. Most studies have now accepted that proton pump inhibitors indeed accelerate the onset of atrophic gastritis in H. pylori-positive patients, but evidence against such an association was published in one recent (Scandinavian) study; conclusions from this study have, however, been challenged by several groups. Some data are available on the efficacy of H. pylori eradication with regard to the prevention of atrophy. The limited significance of the development of parietal cell protrusions and fundic gland cysts is better understood, but much less is known of the development and long-term consequence of H. pylori-induced autoimmune gastritis. Finally, recent studies in H. pylori-positive patients indicate that treatment with proton pump inhibitors may promote bacterial N-nitrosation formation. These data taken together suggest that the eradication of H. pylori may be based not only on morphological arguments, but also on bacterial alterations in the gastric milieu.